BioStock: Elicera’s candidate ELC-100 granted Orphan Drug Designation

Cell and gene therapy company Elicera Therapeutics has been granted Orphan Drug Designation (ODD) by the FDA for its drug candidate ELC-100, intended for the treatment of pancreatic neuroendocrine tumors. This highlights the potential of the oncolytic virus as a promising therapy for this challenging type of cancer.

Read the article at biostock.se:

Elicera’s candidate ELC-100 granted Orphan Drug Designation

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/